Metopenem (Meropenem Equity, Invogem)
Metopenem
Equity Pharmaceutical (Pty) Ltd
Registration
- Applicant
- Equity Pharmaceutical (Pty) Ltd
- Registrations
- 4
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Meropenem 500 equity EACH VIAL CONTAINS MEROPENEM TRIHYDRATE EQUIVALENT TO ANHYDROUS METOPENEM 500,0 mg | 500 | 55084255/20.1.1/0842 | Registered | Not determined | None |
| Meropenem 1 000 equity EACH VIAL CONTAINS MEROPENEM TRIHYDRATE EQUIVALENT TO ANHYDROUS METOPENEM 1 000,0 mg | 1 000 | 55084355/20.1.1/0843 | Registered | Not determined | None |
| Invogem 500 EACH VIAL CONTAINS MEROPENEM TRIHYDRATE EQUIVALENT TO ANHYDROUS METOPENEM 500,0 mg | 500 | 550844.84255/20.1.1/0844.842 | Registered | Not determined | None |
| Invogem 1 000 EACH VIAL CONTAINS MEROPENEM TRIHYDRATE EQUIVALENT TO ANHYDROUS METOPENEM 1 000,0 mg | 1 000 | 550845.84355/20.1.1/0845.843 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
4-Amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Drag to rotate. Structure from PubChem CID 6435808.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.